A retrospective observational study to assess risk and predictors of hyponatremia and other electrolyte abnormalities in patients receiving ICIs to treat advanced malignancies in real-world settings
Latest Information Update: 05 Jan 2021
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; Gastrointestinal cancer; Glioblastoma; Gynaecological cancer; Head and neck cancer; Leukaemia; Lymphoma; Malignant melanoma; Solid tumours; Thoracic neoplasms; Urogenital cancer
- Focus Adverse reactions
- 05 Jan 2021 New trial record
- 29 Dec 2020 Results published in the Nephrology Dialysis Transplantation